Autoimmune hepatitis: Towards a personalized treatment.

Area of Science:

• Hepatology
• Immunology
• Pharmacology

Background:

• Autoimmune hepatitis (AIH) is a chronic liver inflammation affecting adults and children, marked by high IgG and autoantibody levels.
• Current standard treatment involves steroids and azathioprine, achieving remission in about 80% of patients.
• Treatment algorithms for AIH have seen minimal updates in over 40 years, despite significant immunological advancements.

Purpose of the Study:

• To review current treatment options for autoimmune hepatitis.
• To discuss the efficacy and limitations of established and emerging therapies.
• To explore future directions for personalized AIH treatment.

Main Methods:

• Literature review of available treatment options for autoimmune hepatitis.
• Analysis of clinical experiences with various immunosuppressive and biologic agents.
• Discussion of novel therapeutic strategies under investigation.

Main Results:

• Steroids are standard for induction, but alternatives like cyclosporine A and tacrolimus show promise, though with potential side effects.
• Mycophenolate mofetil is an option for azathioprine-intolerant patients.
• B-cell depleting agents (rituximab, belimumab) are effective for refractory AIH.
• Emerging therapies include anti-TNF agents, JAK inhibitors, and CAR T-cell therapy.

Conclusions:

• While steroids and azathioprine remain foundational, a broader range of treatments is now available for AIH.
• Newer agents offer alternatives for induction, maintenance, and refractory disease.
• Future AIH management may involve tailored therapeutic approaches based on individual patient profiles.